Stock Snapshot
| Table Header | Table Header |
|---|---|
| Company | Eli Lilly and Company |
| Sector | Healthcare / Pharmaceuticals / Biotechnology |
| Theme | Obesity Therapies / GLP-1 / Diabetes Innovation |
| Business Model | Development of innovative drugs and biotechnological therapies with a focus on diabetes, obesity, oncology, immunology, and neuroscience |
| ISIN | US5324571083 |
| Market Capitalization | approx. USD 949 billion |
| UMBRELLA Status | Active |
Eli Lilly is one of the world’s leading pharmaceutical companies and is considered one of the primary beneficiaries of global growth in the diabetes and obesity medication market.
The company develops innovative medicines in the fields of metabolic diseases, oncology, immunology, and neuroscience, and invests heavily in research, clinical trials, and production capacities.
The investment case is primarily driven by:
- strong growth in the GLP-1 market
- increasing demand for obesity therapies
- high margins on patent-protected medications
- global expansion of production capacities
- long-term innovation pipeline
- rising healthcare spending worldwide
- increasing importance of personalized medicine
In particular, the medications Mounjaro and Zepbound position Eli Lilly as one of the most important players in the multi-billion dollar market for weight loss and diabetes treatment.
In contrast to classic defensive pharmaceutical stocks, Eli Lilly currently possesses exceptionally dynamic growth potential through new blockbuster drugs and a strong research pipeline.
→ Key variable: GLP-1 growth + drug approvals + global demand for obesity therapies.
